Floatz logo

Aralast Np

Diabetes Mellitus, Type 1

National Institute of Allergy and Infectious Diseases (NIAID)Phase 2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Diabetes Mellitus, Type 1 cohort.

Asset / SponsorPhaseRating
Metformin
Heba M. Ismail
Phase 4A
Liraglutide
Dasman Diabetes Institute
Phase 4BBB
Tirzepatide
Royal North Shore Hospital
Phase 4BBB
Semaglutide
Nordsjaellands Hospital
Phase 3BB
ct-868
Carmot Therapeutics, Inc.
Phase 2BB

View all 23 →

Same molecule, other indications

Aralast Np is also rated in:

chronic obstructive pulmonary diseaseDormant
CC
Indicative ·
47 / 100
View asset →
alpha 1-antitrypsin deficiencyDormant
CC
Indicative ·
47 / 100
View asset →
diabetes mellitusDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →